Oncotarget

Research Perspectives:

Somatostatin receptor 2 targeting in small cell lung carcinoma: perspectives

Jonathan M. Lehman _ and Pierre P. aMassion

PDF  |  Full Text  |  How to cite  |  Order a Reprint

Oncotarget. 2019; 10:4727-4730. https://doi.org/10.18632/oncotarget.27107

Metrics: PDF 398 views  |   Full Text 666 views  |   ?  


Abstract

Jonathan M. Lehman1,2,3 and Pierre P. aMassion1,2,3

1 Division of Medical Oncology, Thoracic Program, Vanderbilt Ingram Cancer Center, Nashville, TN, USA

2 Thoracic Program, Vanderbilt Ingram Cancer Center, Nashville, TN, USA

3 Veterans Affairs, Tennessee Valley Healthcare System, Nashville Campus, Nashville, TN, USA

Correspondence to:

Jonathan M. Lehman,email: jonathan.m.lehman@vanderbilt.edu

Keywords: small cell lung cancer; somatostatin receptor 2; antibody-drug conjugate; peptide drug conjugate; perspectives

Received: June 18, 2019     Accepted: June 29, 2019     Published: July 30, 2019

ABSTRACT

Small Cell lung carcinoma (SCLC) is the most lethal and aggressive subtype of lung cancer. Novel targeting approaches and agents are desperately needed. In this perspectives, we briefly explore recent data published in the International Journal of Cancer suggesting Somatostatin Receptor 2 (SSTR2) as a viable target for SCLC, summarize the current clinical trial space, and describe promising new research and clinical directions for Somatostatin Receptor 2 targeting in SCLC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 27107